Biocon secures Q1 2027 Pebrilzo launch as Motilal Oswal rates Biocon stock Buy

Published on 10/25/2026 at 00:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pebrilzo may launch in Europe in Q1 2027 and the US in Q3 2028. Biocon stock posted INR 43.36 billion revenue in Q1 FY27.

Pebrilzo settlement sets market timetable

Biocon announced its Genentech settlement on October 14, 2026.
Q1 FY27 revenue increased 10.00 percent to INR 43.36 billion.
Biocon's next earnings report is scheduled for November 5, 2026.

Biocon, INE376G01013, Illustration mit AI erstellt.

Biocon Limited secured licensed launch windows for its Pebrilzo biosimilar after a global patent settlement with Genentech on October 14, 2026. The agreement allows launches in the European Union and the United Kingdom in the first quarter of 2027 and in the United States in the third quarter of 2028, subject to regulatory approvals, as Business Standard reported.

Three milestones shape Pebrilzo

On September 8, 2026, Biocon announced a Brazil partnership covering 100.00 percent of the Productive Development Partnership allocation and about 70.00 percent of national pertuzumab demand. On September 21, 2026, the European Medicines Agency's committee recommended marketing authorization for Pebrilzo. On October 14, 2026, the Genentech settlement fixed the earliest licensed launch windows for Europe, the United Kingdom and the United States, according to Financial Express.

What does the deal change?

The settlement improves launch visibility, but it does not create immediate revenue. Biocon reported Q1 FY27 consolidated revenue of INR 43.36 billion, up 10.00 percent year over year, while net profit reached INR 1.41 billion, up from INR 0.31 billion in the year-earlier quarter. Biosimilars revenue increased 16.00 percent to INR 28.55 billion, while services revenue fell 16.00 percent to INR 7.36 billion, according to Financial Express. The figures show a stronger biopharma base, although they do not isolate Pebrilzo revenue.

Next dates and valuation

Biocon's next earnings report is scheduled for November 5, 2026, according to TradingView. On October 23, 2026, Biocon closed at INR 323.50 on the NSE. The finance data showed a 52-week range of INR 318.40 to INR 447.15 and market capitalization of INR 442.0 billion, placing the stock 27.65 percent below its 52-week high.

Biocon stock remains tied to execution

Pebrilzo offers a defined regulatory and commercial timetable, but approvals, competition and pricing will determine how much of that timetable reaches earnings. The stock's next test is the November reporting date, followed by evidence that the launch windows translate into supply and commercial agreements.